NCT05421832Befejeződött
A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. júl. 24.
Rövid összefoglaló (regiszter, angolul)
The aim of this research program is to develop and validate a smartphone app-based digital measurement concept that: * Objectively quantifies the severity of Parkinson's Disease (PD) related vocal and speech symptoms; * Accurately and sensitively identifies vocal and speech abnormalities associated with the prodromal stage of PD.
- Állapot (regiszter)
- Befejeződött
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 91 (tényleges)
- Első benyújtás
- 2022. jún. 8.
- Kezdés
- 2022. szept. 27.
- Elsődleges befejezés
- 2025. jún. 30.
- Fő szponzor
- Northwestern University
- Betegségek
- Parkinson-kór
- NCT-szám
- NCT05421832
Mit vállalsz
- Vizsgálat típusa: Megfigyeléses
- Bevont résztvevők: 91
- 2022. szept. 27. és az elsődleges befejezés (2025. jún. 30.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- History of drug and/or alcohol abuse within the past year prior to Screening Visit.
- Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).
- History of drug and/or alcohol abuse within the past year prior to Screening Visit.
- Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).
- History of drug and/or alcohol abuse within the past year prior to Screening Visit.
Más betegség
- Symptomatic or atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).
- Current or active clinically significant neurological disorder other than PD (in the opinion of the Investigator).
- Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
- Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation.
- Prodromal PD:
- Clinical diagnosis of PD, other parkinsonism, or dementia.
- Any current or active clinically significant neurological disorder (in the opinion of the Investigator).
- Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
- Any current or active clinically significant neurological disorder (in the opinion of the Investigator).
- Significant cognitive impairment or clinical dementia at Screening that, in the opinion of the Investigator, would interfere with study evaluation.
- Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation
Életkor
- Any other medical or psychiatric condition, which in the opinion of the investigator might preclude participation.
- Age \& Sex Matched Healthy Control:
Egyéb
- PD:
- Late-stage PD diagnosis (i.e., Hoehn \& Yahr Stage 5) at Screening Visit
- Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
- Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
- First degree relative with PD (i.e., biologic parent, sibling, child).
- Inability or unwillingness to complete all aspects of the study - including use of a provisioned smartphone for study assessments; completion of telehealth assessments.
Kiket keres a vizsgálat
- PD:
- Male or female age 30 years or older at Screening Visit.
- Diagnosis of PD as defined by MDS PD diagnostic criteria [1]
- PD severity at Screening Visit of either:
- PD Hoehn and Yahr Stage 1-2, inclusive (PD Cohort I)
- PD Hoehn and Yahr Stages 3-4, inclusive (PD Cohort II)
- Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments.
- Able to provide informed consent.
- Prodromal PD:
- Confirmation that participant is eligible based on clinician determined predictive criteria of known risk of PD including
- Rapid eye movement sleep behavior disorder (RBD), possible, probable or definite, OR
- Hyposmia defined as less than 10th percentile on University of Pennsylvania Smell Identification Test (UPSIT), age and gender adjusted, OR
- Known genetic variants associated with PD risk, AND Confirmed eligible DAT scan.
- Male or female age 30 or older at Screening Visit.
- Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments
- Able to provide informed consent.
- Age \& Sex Matched Healthy Control:
- Male or female age 30 years or older at Screening visit.
- Able and willing to complete all aspects of the study, including at home smartphone app and Zoom telehealth assessments
- Able to provide informed consent.
Életkor a regiszterben: 30 év – - · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Northwestern University | Chicago | Egyesült Államok | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.